OBJECTIVE: To determine the incidence of inflammatory arthritis and autoantibody prevalence in Indigenous North American people. METHODS: Unaffected relatives of Indigenous North Americans with rheumatoid arthritis (RA) from central Canada and Alaska were systematically monitored from 2005 to 2017. Rheumatoid factor (RF) and anti-citrullinated protein antibodies (ACPAs) were tested at every visit, and a subset was tested for ACPA fine specificity using a custom multiplex assay. Multistate models based on all available study visits were developed to determine the likelihood of transitioning between autoantibody states, or to inflammatory arthritis. RESULTS: Eighteen of 374 relatives (4.8%) developed inflammatory arthritis during follow-up (after a mean ± SD of 4.7 ± 2.4 years), yielding a transition rate of 9.2 cases/1,000 person-years. Thirty percent of those who developed inflammatory arthritis were seronegative at baseline, but all were seropositive at inflammatory arthritis onset. Although 30% of ACPA/RF double-seropositive individuals developed inflammatory arthritis (after 3.2 ± 2.2 years), the majority of these individuals did not develop inflammatory arthritis. Multistate modeling indicated a 71% and 68% likelihood of ACPA and RF seropositive states, respectively, reverting to a seronegative state after 5 years, and a 39% likelihood of an ACPA/RF double-seropositive state becoming seronegative. Fine specificity testing demonstrated an expansion of the ACPA repertoire prior to the development of inflammatory arthritis. CONCLUSION: Despite a high incidence of inflammatory arthritis in this cohort of at-risk relatives of Indigenous North Americans with RA, a large proportion of autoantibody-positive individuals do not develop inflammatory arthritis and revert back to an autoantibody-negative state.
OBJECTIVE: To determine the incidence of inflammatory arthritis and autoantibody prevalence in Indigenous North American people. METHODS: Unaffected relatives of Indigenous North Americans with rheumatoid arthritis (RA) from central Canada and Alaska were systematically monitored from 2005 to 2017. Rheumatoid factor (RF) and anti-citrullinated protein antibodies (ACPAs) were tested at every visit, and a subset was tested for ACPA fine specificity using a custom multiplex assay. Multistate models based on all available study visits were developed to determine the likelihood of transitioning between autoantibody states, or to inflammatory arthritis. RESULTS: Eighteen of 374 relatives (4.8%) developed inflammatory arthritis during follow-up (after a mean ± SD of 4.7 ± 2.4 years), yielding a transition rate of 9.2 cases/1,000 person-years. Thirty percent of those who developed inflammatory arthritis were seronegative at baseline, but all were seropositive at inflammatory arthritis onset. Although 30% of ACPA/RF double-seropositive individuals developed inflammatory arthritis (after 3.2 ± 2.2 years), the majority of these individuals did not develop inflammatory arthritis. Multistate modeling indicated a 71% and 68% likelihood of ACPA and RF seropositive states, respectively, reverting to a seronegative state after 5 years, and a 39% likelihood of an ACPA/RF double-seropositive state becoming seronegative. Fine specificity testing demonstrated an expansion of the ACPA repertoire prior to the development of inflammatory arthritis. CONCLUSION: Despite a high incidence of inflammatory arthritis in this cohort of at-risk relatives of Indigenous North Americans with RA, a large proportion of autoantibody-positive individuals do not develop inflammatory arthritis and revert back to an autoantibody-negative state.
Authors: David Vega-Morales; María Del Carmen Larios-Forte; Lorena Pérez-Barbosa; Jorge Antonio Esquivel-Valerio; Mario Alberto Garza-Elizondo; Cassandra Michelle Skinner-Taylor; Brenda Roxana Vázquez-Fuentes; Diana Elsa Flores-Alvarado; Miguel Ángel Villarreal-Alarcón; Iván de Jesús Hernández-Galarza; Luis Iván Lozano-Plata; Martha Mariana Castañeda-Martínez; Diana Daniela Castañeda-Martínez; Pablo Herrera-Sandate; Jesus Alberto Cardenas-de la Garza; Dionicio Ángel Galarza-Delgado Journal: Clin Rheumatol Date: 2022-01-28 Impact factor: 2.980
Authors: Vanessa L Kronzer; Cynthia S Crowson; Jeffrey A Sparks; Elena Myasoedova; John Davis Journal: Arthritis Care Res (Hoboken) Date: 2021-02 Impact factor: 4.794
Authors: Fenne Wouters; Marc P Maurits; Laurette van Boheemen; Marloes Verstappen; Kulveer Mankia; Xanthe M E Matthijssen; Annemarie L Dorjée; Paul Emery; Rachel Knevel; Dirkjan van Schaardenburg; René E M Toes; Annette H M van der Helm-van Mil Journal: Ann Rheum Dis Date: 2021-07-20 Impact factor: 19.103
Authors: Elizabeth A Bemis; M Kristen Demoruelle; Jennifer A Seifert; Kristen J Polinski; Michael H Weisman; Jane H Buckner; Peter K Gregersen; Ted R Mikuls; James R ODell; Richard M Keating; Kevin D Deane; V Michael Holers; Jill M Norris Journal: Ann Rheum Dis Date: 2020-09-14 Impact factor: 27.973
Authors: Liam J O'Neil; Ana Barrera-Vargas; Donavon Sandoval-Heglund; Javier Merayo-Chalico; Eduardo Aguirre-Aguilar; Angel M Aponte; Yanira Ruiz-Perdomo; Marjan Gucek; Hani El-Gabalawy; David A Fox; James D Katz; Mariana J Kaplan; Carmelo Carmona-Rivera Journal: Sci Adv Date: 2020-10-28 Impact factor: 14.136